Novartis AG (NOVNz)

BATS Europe
Currency in CHF
97.710
-0.570(-0.58%)
Closed
NOVNz Scorecard
Full Analysis
Management has been aggressively buying back shares
Fair Value
Day's Range
97.54099.305
52 wk Range
83.660102.720
Key Statistics
Edit
Bid/Ask
97.71 / 97.71
Prev. Close
98.28
Open
99.22
Day's Range
97.54-99.305
52 wk Range
83.66-102.72
Volume
334.83K
Average Volume (3m)
306.28K
1-Year Change
9.09%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NOVNz Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 29 consecutive years
Show more

Novartis AG Company Profile

Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still’s disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Employees
75883

Compare NOVNz to Peers and Sector

Metrics to compare
NOVNz
Peers
Sector
Relationship
P/E Ratio
18.0x20.8x−0.6x
PEG Ratio
−1.040.280.00
Price/Book
4.9x2.3x2.6x
Price / LTM Sales
4.2x3.2x3.1x
Upside (Analyst Target)
-−1.2%51.7%
Fair Value Upside
Unlock11.4%7.5%Unlock

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 5.92
Dividend Yield
3.56%
Industry Median 1.27%
Annualised payout
3.5000
Paid annually
5-Years Growth
+4.36%
Growth Streak

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Novartis (NOVNz) Stock Price Today?

The Novartis stock price today is 97.71

What Stock Exchange Does Novartis Trade On?

Novartis is listed and trades on the BATS Europe stock exchange.

What Is the Stock Symbol for Novartis?

The stock symbol for Novartis is "NOVNz."

Does Novartis Pay Dividends? What’s The Current Dividend Yield?

The Novartis AG dividend yield is 3.56%.

What Is the Novartis Market Cap?

As of today, Novartis market cap is 192.97B.

What is Novartis Earnings Per Share?

The Novartis EPS is 5.92.

From a Technical Analysis Perspective, Is NOVNz a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.